Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
95%
Monoclonal Antibody
87%
Diseases
84%
Phase I Trials
80%
Idiopathic Thrombocytopenic Purpura
74%
Neoplasm
72%
Malignant Neoplasm
67%
Nonhodgkin Lymphoma
66%
Non Small Cell Lung Cancer
55%
Adverse Event
54%
Pharmacokinetics
54%
Clinical Trial
54%
Breast Cancer
53%
Carboplatin
46%
Overall Survival
45%
Solid Malignant Neoplasm
44%
Rituximab
42%
Cetuximab
39%
Eltrombopag
39%
Bevacizumab
39%
Iodine-131
37%
Docetaxel
37%
Prostate Cancer
37%
Maximum Tolerated Dose
36%
Progression Free Survival
36%
Phase II Trials
35%
Gemcitabine
33%
Paclitaxel
33%
Antitumor Activity
32%
Metastatic Breast Cancer
28%
Doxorubicin
28%
Metastatic Colorectal Cancer
26%
Placebo
25%
Receptor
25%
Castration Resistant Prostate Cancer
24%
Thrombocytopenia
20%
Subcutaneous Injection
20%
Neutropenia
19%
Metastatic Melanoma
19%
Edrecolomab
19%
Ibritumomab Tiuxetan
19%
Prednisone
19%
Combination Therapy
18%
Adenocarcinoma
18%
Carcinoembryonic Antigen
18%
Abiraterone Acetate
18%
Androgen
17%
Immunoglobulin
17%
Epidermal Growth Factor Receptor
17%
Digestive System Cancer
16%
Medicine and Dentistry
Breast Cancer
100%
Idiopathic Thrombocytopenic Purpura
59%
Malignant Neoplasm
42%
Platelet
37%
Eltrombopag
33%
Neoplasm
32%
Diseases
30%
Monoclonal Antibody
29%
Awareness
28%
Clinical Trial
27%
COVID-19
26%
Bevacizumab
26%
Low and Middle Income Countries
22%
Low Drug Dose
22%
Placebo
21%
Adverse Event
21%
Arm
20%
Non-Hodgkin Lymphoma
19%
Iodine 131
19%
Metastatic Colorectal Cancer
19%
B Cell
17%
Triple Negative Breast Cancer
16%
Prevalence
16%
Tumor
15%
Progression Free Survival
15%
Overall Survival
15%
Quality of Life
14%
CD20
13%
Cancer
13%
Antibody-Drug Conjugate
13%
Glembatumumab Vedotin
13%
Metastatic Melanoma
13%
Glycoprotein
13%
Tositumomab
13%
Veltuzumab
13%
Arsenic Trioxide
13%
Phase I Trials
13%
Solid Malignant Neoplasm
13%
Letrozole
13%
Postmenopause
13%
Carboplatin
13%
Gemcitabine
13%
Bendamustine
13%
Cancer Diagnosis
13%
Radiation Therapy
13%
Colorectal Carcinoma
13%
Severe Acute Respiratory Syndrome Coronavirus 2
13%
Clinician
11%
Chemotherapy
11%
Infusion
11%
Immunology and Microbiology
Platelet
47%
Monoclonal Antibody
38%
Immune Response
37%
Colorectal Carcinoma
36%
Idiopathic Thrombocytopenic Purpura
33%
Pharmacokinetics
27%
Intravenous Immunoglobulin
25%
Arm
22%
Antibody Response
22%
Glycoprotein
19%
Iodine-131
19%
Human Immunoglobulin
16%
Fc Receptor
15%
In Vitro
14%
T Cell
13%
Antiidiotypic Antibody
13%
Glembatumumab Vedotin
13%
Antibody Drug Conjugate
13%
Carcinoembryonic Antigen
13%
Edrecolomab
13%
Interferon Type I
13%
COVID-19
13%
Thrombocyte Membrane
12%
Blood Plasma
11%
Murine
11%
Maximum Tolerated Dose
10%
Platelet Count
10%
Interleukin 2 Receptor
9%
Microbiome
9%
Blood Level
9%
Tumor Antigen
9%
Immunoglobulin G
9%
Low Drug Dose
8%
Plasma Half Life
8%
Immunoglobulin G4
8%
Biological Product
8%
CD20
7%
Immunoglobulin G1
7%
Lupus Erythematosus
7%
Wild Type
7%
Rituximab
7%
Antigen Expression
7%
Chimeric Antibody
6%
CD16
6%
Cyclophosphamide
6%
Tigatuzumab
6%
Veltuzumab
6%
Trastuzumab
6%
Etaracizumab
6%
Somatomedin
6%